Related Experiment Videos
Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors
Journal of Medicinal Chemistry
|February 1, 1985
Abstract:
The synthesis and structure-activity profile of a new class of potent and highly specific thromboxane A2 synthetase inhibitors is described. The most potent member of this series in vitro is determined to be imidazo[1,5-a]-pyridine-5-hexanoic acid (9).
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Complications during repeated tracheal intubation in the Intensive Care Unit. A prospective, observational study comparing the first intubation and the reintubation.
Revista espanola de anestesiologia y reanimacion·2021
Oral theophylline for chronic obstructive pulmonary disease.
The Cochrane database of systematic reviews·2003
Congenital diaphragmatic hernia and hydrops: a lethal association?
Journal of pediatric surgery·2002
Nitric oxide donors induce large-scale deletion mutations in human lymphoblastoid cells: implications for mutations in T-lymphocytes from arthritis patients.
Environmental and molecular mutagenesis·2002
Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.
Journal of medicinal chemistry·2001
6-(4-Benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D(4) receptors.
Bioorganic & medicinal chemistry·2001
Structural and Mechanistic Studies of ADEPs Yield Potent Antibacterials and a Drug Formulation Strategy for Tuberculosis.
Journal of medicinal chemistry·2026
A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma.
Journal of medicinal chemistry·2026
From Fragment Hit to Clinical Candidate: Discovery of Dual H1R/H4R Ligands with Superior Efficacy in Allergic Conjunctivitis.
Journal of medicinal chemistry·2026
Potent Anticancer Tethered Organorhodium(III) Complexes Target the Mitochondria.
Journal of medicinal chemistry·2026
Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models.
Journal of medicinal chemistry·2026
Lead Optimization of Multimutant KRAS Switch-II Pocket Macrocyclic Inhibitors via Isosteric Replacement to Improve ADME and Oral Exposure.
Journal of medicinal chemistry·2026
Methods of predicting clinically significant DRUG-DRUG interactions beyond validated interaction checkers.
Expert opinion on drug metabolism & toxicology·2026
Cholinesterase Inhibitors in Alzheimer's Disease: Medicinal Chemistry, Mechanistic Insights, and Emerging Multitarget Strategies.
CNS & neurological disorders drug targets·2026
Discovery of a Caffeic Acid Thioamide with Potent Activity against Pathogenic Fungi and Fluconazole Tolerance-Eliminating Effects in Candida albicans.
Drug design, development and therapy·2026